techniques including MALS (Multi-Angle Light Schattering), X-ray crystallographyic, and SAXS (Small Angle X-ray Scattering) to better understand the nature of the active conformation of GAC and ultimately, how the recently described glutaminase inhibitor 968 (J.B., Wang; Cancer Cell, 2010) interacts with GAC and renders it inactive. Our results support a model whereby GAC binds phosphate that results in a change in glutaminase oligomerization, which results in active tetramers as well as higher oligomeric species. Effects of the drug 968 on the activation/oligomerization state of glutaminase will also be discussed.

3151-Pos   Board B12
A Systematic Computational Method to Predict and Enhance Antibody-Antigen Binding in the Absence of Antibody Crystal Structures
Jianqing Xu[1], Aleksandr E. Miklos[2], Randy Hughes[2], Brian Kuhlman[3], George Georgiou[2], Andrew D. Ellington[2], Jeffrey J. Gray[1].
[1]Johns Hopkins University, Baltimore, MD, USA, [2]University of Texas at Austin, Austin, TX, USA, [3]University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Structure-based design efforts on antibodies are frequently hamstrung by the general difficulty of crystallizing antibody molecules. Computational approaches are getting more success and playing a very important role in protein structure prediction and design. A combined platform with both computational predication and experimental verification would have a transformative research capability on antibody engineering. We have been developing and integrating RosettaAntibody (homology modeling and H3 loop modeling), RosettaDock (SnugDock and EnsembleDock) and RosettaDesign (non-canonical amino acids design) into a systematic computational pipeline. Using the targets of M18/Anthrax complex, which has solved crystal structure, and anti-MS2/MS2 complex, whose antibody structure is not available, the new pipeline is capable of building homology models for antibody from its sequence, and predicting the docked antibody-antigen structures. The correct antigen epitope can be identified by iteratively refining the predicted candidates with experimental verifications such as interface alanine scanning. This is followed by computational CDR designs utilizing non-canonical amino acids, which can form covalent bonds with epitope residues. Along with experimental confirmations, the incorporation of the systematical computational method was proved to significantly facilitate the epitope identification and non-canonical amino acid designs. These efforts eventually substantially increased the antibody-antigen binding affinity of the two targets.

3152-Pos   Board B13
A Molecular Dynamics Simulation of Peptide-Triazole HIV Entry Inhibitor Binding to gp120 Hydrophobic Core
Ali Emileh[1,2], Ferit Tuzer[2], Diogo R. Moreira[2], Judith M. LaLonde[3], Carole A. Bewley[4], Irwin M. Chaiken[2], Cameron F. Abrams[1].
[1]Chemical & Biological Engineering, Drexel University, Philadelphia, PA, USA, [2]Biochemistry, Drexel University College of Medicine, Philadelphia, PA, USA, [3]Chemistry, Bryn Mawr College, Bryn Mawr, PA, USA, [4]Bioorganic Chemistry, NIDDK, NIH, Bethesda, MD, USA.
The envelope spike on HIV surface is a non-covalent trimer of gp120 and gp41 dimers; with gp120 responsible for binding to the CD4 receptor and the mandatory coreceptor, CCR5 or CXCR4. Blocking the gp120-CD4 or gp120-coreceptor interaction can block viral entry and infection. The HNG family of peptides (sequence RINNIXWSEAMM, X= derivatized azidoproline) is a promising class of dual-site entry inhibitors thought to allosterically inhibit the binding process and trap the flexible gp120 molecule in an inactive state. To date, there have been no reports on the structure of the peptide or the peptide/gp120 complex. Here we have used Molecular Dynamics to develop a docking model in which the peptide binds in a tripartite fashion, preventing the formation of the bridging sheet in gp120, which is necessary for coreceptor attachment and initiation of entry. The protein undergoes significant induced fit conformational changes involving movement of large loops which allows the peptide to bind tightly. Our model is consistent with experimental observations on the peptide footprint on gp120, pointing to a hydrophobic core underneath the bridging sheet and close to the F43 pocket as the putative binding site. Our results provide an explanation for why the stereochemistry of the triazole moiety on the proline is important for peptide function, in addition to explaining the inactivity of D-tryptophan in the sequence. Furthermore, saturation transfer difference (STD) NMR experiments point to the I-X-P hydrophobic center on the peptide as the central contact point in the complex, which is consistent with the peptide pose proposed in MD studies. Our model may provide a unique basis for rational design of allosteric entry inhibitors of HIV and ultimately small molecule inhibitors of viral entry.

3153-Pos   Board B14
Evaluating the Potency of Small Molecules to Combat Resistance Based on Docking Structures: An Application to the HIV Protease
Bo Ding, Nan Li, Wei Wang.
UCSD, San Diego, CA, USA.
HIV-1 protease is an important drug target for the therapy of AIDS. Up to date nine protease drugs have been approved by the U.S. Food and Drug Administration. However, the efficacy of these drugs is limited by the drug-resistant mutants of the protease which can become dominant in the viral population in several months. As it often takes years of effort and millions of dollars to develop a drug, evaluating the potency of a compound to combat resistance at the early stage of drug development would is no doubt invaluable. In this study, we present a new procedure to predict HIV protease mutants that can be resistant to a specific compounds based on docking structure. We exploited molecular interaction energy components (MIECs) between the ligand and the protease residues to characterize the docking poses. A classification method called Support Vector Machine (SVM) is then employed to distinguish resistant from non-resistant mutants. Most interestingly, leave-one-drug-out test showed that our strategy can be generalized to evaluate potency of new drug lead, which suggests the possibility of evaluating the potency to combat resistance for small molecules found from virtual screening.

3154-Pos   Board B15
Reconstituted High Density Lipoprotein Bearing Apolipoprotein E3 Serves as a Nanovehicle to Transport and Target Bioflavonoids such as Resveratrol
Sea H. Kim, Vasanthy Narayanaswami.
California State University, Long Beach, Long Beach, CA, USA.
The objective of this study is to transport resveratrol, an antioxidant and anti-inflammatory bioflavonoid, in the plasma to targeted sites. Resveratrol is a phytoalexin polyphenol that is found in natural products such as grape skins, cocoa, and is a constituent of red wine. It appears to be a potent factor as an anti-cancer and atheroprotective agent. The ''French Paradox'' (French suffering a relatively lower incidence of coronary heart disease compared to other western societies) has been attributed to the benefits of resveratrol (as a result of higher consumption of red wine by the French). However, it is difficult to achieve effective concentrations of resveratrol in plasma via the oral tract from natural resveratrol-rich products. Its low aqueous solubility appears to limit the use of resveratrol as a nutraceutical agent. We propose to employ apolipoprotein E3 (apoE3)-containing reconstituted high density lipoproteins (rHDL) for transportation and targeted delivery of resveratrol. rHDL are water soluble lipoprotein complexes composed of a bilayer of phospholipids surrounded by apoE3, which bears high affinity binding sites for the cell surface localized low density lipoprotein receptor (LDLr). The phospholipid microenvironment of rHDL is expected to provide a centrally located lipid milieu into which resveratrol may be sequestered, and shielded from modification and/or degradation. Our data indicates that resveratrol has effectively partitioned into the hydrophobic milieu of the phospholipid bilayer of rHDL without significant alteration to the conformation of apoE3. Importantly, the presence of resveratrol did not alter the LDLr binding ability of apoE3. These results indicate that rHDL bearing the apoE3 LDLr binding domain can serve as an effective ''nanovehicle'' to transport and potentially deliver resveratrol to targeted sites across the cell membrane.

3155-Pos   Board B16
Design of An Ultra-Fast Acting Insulin Analog using Unnatural Amino Acids - Replacement of PheB24 with Cyclohexanylalanine
Vijay Pandyarajan, Zhuli Wan, Nalinda Wickramasinghe, Jonathan Whittaker, Nelson B. Phillips, Michael A. Weiss.
Case Western Reserve University, Cleveland, OH, USA.
Insulin replacement therapy is central to the treatment of Type 1 diabetes mellitus (T1DM). Clinical trials have shown that tight glycemic control in T1DM leads to reduction in long-term diabetic complications. In an effort to better mimic the normal post-prandial pattern of pancreatic insulin release, mealtime insulin analogs were developed in the 1990s using standard mutagenesis. These analogs exhibit more rapid absorption from the subcutaneous depot due to destabilization of the zinc insulin hexamer. Unfortunately, such conventional analogs do not achieve the rapid ''on-off'' pharmacodynamic profiles sought in an ideal rapid-acting insulin formulation. To circumvent this limitation, we have investigated the utility of nonstandard protein design based on unnatural mutagenesis. Our studies have focused on residue PheB24 at the dimer interface of the insulin hexamer. Investigation of the role of this aromatic side chain by hybrid quantum-mechanical/classical molecular mechanics (QM/cMM) suggested that substitution of the B24 aromatic ring of its saturated